NasdaqGM:CRMDPharmaceuticals
CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives
CorMedix (CRMD) has opened 2026 with Q1 revenue of US$127.4 million and basic EPS of US$0.49, set against a very large year over year earnings expansion and a move in net profit margin from 20.8% to 45% over the past 12 months. The company has seen quarterly revenue step up from US$39.1 million in Q1 2025 to US$127.4 million in Q1 2026. Trailing twelve month EPS has moved from US$0.28 at the start of 2025 to US$2.38 by Q1 2026. This gives investors a results set where wider margins and higher...